Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. NEW YORK ( TheStreet) -- Myriad Genetics (Nasdaq: MYGN) hit a new 52-week high Thursday as it is currently trading at $36.39, above its previous 52-week high of $34.70 with 1.2 million shares traded as of 10:31 a.m. ET. Average volume has been 1.1 million shares over the past 30 days. Myriad has a market cap of $2.73 billion and is part of the services sector and diversified services industry. Shares are up 25.7% year to date as of the close of trading on Wednesday. Myriad Genetics, Inc., a molecular diagnostic company, focuses on the development and marketing of predictive medicine, personalized medicine, and prognostic medicine tests primarily in the United States. The company has a P/E ratio of 21.8, above the S&P 500 P/E ratio of 17.7.
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.